GLP-1 receptor agonists and SGLT2 inhibitors both reduce cardiovascular risk in type 2 diabetes patients, but through complementary mechanisms — GLP-1 drugs fight atherosclerosis while SGLT2 inhibitors protect through metabolic and fluid balance effects.
2 complementary pathwaysGLP-1 drugs target atherosclerosis while SGLT2 inhibitors target fluid/metabolic balance — different mechanisms for heart protection
What the researchers found
GLP-1 receptor agonists reduce cardiovascular risk primarily through anti-atherosclerotic effects: they improve endothelial function, reduce inflammation, prevent blood clot formation, and stabilize arterial plaques. SGLT2 inhibitors achieve cardiovascular protection through different mechanisms: increasing sodium excretion, reducing plasma volume, promoting ketone body utilization in heart and kidney tissue, and lowering oxidative stress and uric acid levels.
The review concludes that these complementary mechanisms make the two drug classes suitable for different patient profiles, and their combination may offer additive cardiovascular benefits.
Why it matters
Heart disease is the leading cause of death in people with type 2 diabetes. Having two drug classes that protect the heart through entirely different pathways opens the door to personalized treatment — choosing GLP-1 drugs for patients with atherosclerosis risk versus SGLT2 inhibitors for those with heart failure or kidney concerns, or combining both for maximum protection. This review helps clinicians navigate these decisions with current evidence.
How the study worked
This is a comparative literature review synthesizing current evidence on the mechanisms of action, cardiovascular risk-reducing efficacy, and safety profiles of GLP-1 receptor agonists and SGLT2 inhibitors. The authors focused on identifying practical clinical factors that guide treatment selection between these two drug classes.
What this study cannot tell us
As a narrative review, this paper synthesizes existing literature rather than presenting new clinical data. The comparison of mechanisms is based on current understanding, which continues to evolve. The review does not include meta-analytic quantification of effect sizes or head-to-head trial data comparing the two drug classes directly. Some proposed mechanisms (e.g., ketone body utilization for SGLT2 inhibitors) are still being validated.
How to read the evidence
This is a narrative review drawing on published clinical trial data and mechanistic studies. While it synthesizes high-quality evidence from landmark cardiovascular outcome trials, the review itself does not generate new data or conduct systematic analysis.
When this study was published
Published in 2025, this review incorporates the latest evidence on cardiovascular benefits of both drug classes and reflects current clinical guidelines and prescribing practices.
The bigger picture
The cardiovascular benefits of GLP-1 receptor agonists and SGLT2 inhibitors have reshaped diabetes treatment guidelines worldwide. These drugs are now recommended not just for blood sugar control but specifically for cardiovascular and kidney protection. Understanding their distinct mechanisms is critical as the field moves toward precision medicine, where treatment choices are tailored to individual patient risk profiles rather than using a one-size-fits-all approach.
Questions still open
- Do patients receive significantly greater cardiovascular protection from combining GLP-1 receptor agonists with SGLT2 inhibitors compared to either drug alone?
- Are there specific cardiovascular risk profiles where one drug class clearly outperforms the other?
- How do the newer dual and triple agonists (like tirzepatide) compare to the combination of a GLP-1 RA plus an SGLT2 inhibitor?
Common questions
What's the main difference between how GLP-1 drugs and SGLT2 inhibitors protect the heart?
Can you take both a GLP-1 drug and an SGLT2 inhibitor at the same time?
Read the original research
Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction.
Biomedicines, 13(11)
Citation
Homoródi, Nóra; Varga, Éva; Szabó, Zoltán; Sztanek, Ferenc; Harangi, Mariann. (2025). Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction.. Biomedicines, 13(11). https://doi.org/10.3390/biomedicines13112595